Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Human Acellular Vessel (HAV; Humacyte Inc.) for Vascular Trauma

Human Acellular Vessel (HAV; formerly Humacyl) (Humacyte Inc.) is an off-the-shelf bioengineered vascular conduit proposed for urgent arterial repair following extremity vascular trauma when a synthetic graft is not indicated, and when autologous vein use is not feasible.

Darvadstrocel (Takeda Pharmaceutical Co. Ltd.) for Perianal Fistula in Crohn Disease

Darvadstrocel is an injectable allogeneic, expanded, adipose-derived mesenchymal stem cell product. It is proposed as an adjunct to standard medical care for treatment-refractory complex perianal fistula in adults with Crohn disease. Darvadstrocel is in phase III clinical trial development for a future regulatory filing with the FDA. It is currently approved under the brand n…